{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}],"title":"Patients Who Completed 1 12-Week Cycle (C1)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Patients Who Completed 2 12-Week Cycles (C2)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Discontinue Tx During C1: Patient/Physician Choice"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Discontinue Tx During C1: Progressive Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Discontinue Tx During C1:Treatment Toxicity"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"Discontinue Tx After C1: Progressive Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Discontinue Tx After C1: Treatment Toxicity"}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"Tolerability of Therapy was assessed through use of the National Cancer Institute Common Toxicity Criteria (version 3.0). Treatment tolerability was determined based upon whether or not the physician determined therapy was in the patient's best interest, whether the patient wanted to continue therapy or not, whether patients discontinued treatment due to progressive disease, or whether patients discontinued treatment due to toxicity.","groups":[{"description":"ATO dosing was based on the phase 2 European Union regimen at a dose of 0.25 mg/kg administered intravenously on Days 1 through 5 during Week 1 and then twice weekly during Weeks 2 to 12, and GO at a dose of 3mg/m2 on Day 8 for 1 or 2 cycles of 12 weeks each.","id":"OG000","title":"ATO (0.25mg/kg) and GO (3mg/m2)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"12 Weeks","title":"Tolerability","type":"SECONDARY","unitOfMeasure":"participants"}